New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 14, 2014
05:55 EDTKO, KO, KO, KO, WM, WM, WM, WM, NHI, NHI, NHI, NHI, NCLH, NCLH, NCLH, NCLH, MDT, MDT, MDT, MDT, HTA, HTA, HTA, HTA, DSX, DSX, DSX, DSX, CMLS, CMLS, CMLS, CMLS, CHH, CHH, CHH, CHH, WWW, WWW, WWW, WWWNotable companies reporting before Tuesday's open
Notable companies reporting before Tuesday's open, with earnings consensus, include Coca-Cola (KO), consensus 46c; Choice Hotels (CHH) consensus 46c; Cumulus Media (CMLS), consensus 8c; Diana Shipping (DSX), consensus (6c); Healthcare Trust of America (HTA), consensus 17c; Medtronic (MDT), consensus 91c; Norwegian Cruise Line (NCLH), consensus 18c; National Health Investors (NHI), consensus 18c; Waste Management (WM), consensus 60c; Wolverine World Wide (WWW), consensus 20c. The Fly notes that in observation of the Presidents' Day holiday, U.S. markets will be closed on Monday, February 17.
News For KO;CHH;CMLS;DSX;HTA;MDT;NCLH;NHI;WM;WWW From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
March 25, 2015
08:33 EDTNCLHCentury Casinos terminates concession agreements with Oceania, Several Seas
Subscribe for More Information
March 23, 2015
09:20 EDTDSXDiana Shipping announces continuation of time charter agreement for Oceanis
Subscribe for More Information
March 20, 2015
10:00 EDTNCLHOn The Fly: Analyst Initiation Summary
Subscribe for More Information
06:20 EDTNCLHNorwegian Cruise Line initiated with an Outperform at Wedbush
Subscribe for More Information
March 19, 2015
06:53 EDTKOCoca-Cola CEO to raise marketing budget, revamp distribution network, WSJ says
Subscribe for More Information
March 18, 2015
10:31 EDTKOPepsiCo's valuation low vs. peers, says Credit Suisse
Subscribe for More Information
09:36 EDTKOActive equity options trading on open
Subscribe for More Information
09:05 EDTCMLSCumulus Media appoints Pierre Bouvard as Chief Marketing Officer
Subscribe for More Information
07:17 EDTNCLHNorwegian Cruise Line price target raised to $60 from $51 at Credit Suisse
Subscribe for More Information
05:39 EDTMDTSt. Jude Medical downgraded to Market Perform from Outperform at Wells Fargo
Wells Fargo downgraded St. Jude Medical (STJ) to Market Perform saying competitive pressures will drive 2015 market share losses in the company's cardiac rhythm management business, which represents 50% of total sales. Wells believes the launch of CardioMEMS will not be strong enough to offset the headwinds in CRM unit. The firm thinks Boston Scientific's (BSX) earlier than expected approval for its next generation subcutaneous implantable cardioverter-defibrillator called Emblem will drive share gains against St. Jude and Medtronic (MDT) in the single chamber ICD market. Wells cut its price target range for St. Jude shares to $69-$70 from $73-$74. The medical technology company closed yesterday down $2.01 to $65.45.
March 17, 2015
16:00 EDTKOOptions Update; March 17, 2015
iPath S&P 500 VIX Short-Term Futures down 11c to 27.30. Option volume leaders: AAPL RIG MGM HTZ TWTR TSLA CY KO NFLX C according to Track Data.
March 16, 2015
13:16 EDTMDTAnalysts upbeat on results of Edwards' Sapien 3 data
The shares of Edwards Lifesciences (EW) are rising after the company released data on its Sapien 3 transcathter aortic valve over the weekend. In notes to investors today, a number of analysts were upbeat on the data. BACKGROUND: Edwards yesterday announced that high- and intermediate-risk patients treated with Sapien 3 demonstrated lower mortality rates than patients treated with previous transcathter aortic valves, or TAVR, made by the company. The patients also had excellent clinical outcomes in the other primary endpoints of stroke and paravalvular regurgitation, the company stated. Meanwhile, a five year study of patients treated with the first generation SAPIEN device showed that the patients had equivalent outcomes to traditional open-heart surgery, and no structural valve deterioration requiring intervention, the company stated. ANALYST REACTION: Edwards' Sapien 3 data was impressive, as the device showed one of the lowest stroke and mortality rates of any major TAVR study so far, Bernstein analyst Derrick Sung wrote in a note to investors earlier today. Data presented by Edwards and other companies at the American College of Cardiology, or ACC, conference this weekend caused investors and the medical community to become more optimistic about the potential for TAVR devices to replace surgical valves, Sung stated. The analyst wrote that he continues to believe that investors are underestimating the potential size of the TAVR market. Also upbeat on Edwards' data was Wells Fargo, which wrote that the data exceeded high expectations and could pressure the FDA to approve Sapien 3 for intermediate risk patients earlier than Edwards' guidance of late 2016. WHAT'S NOTABLE: Analysts were also upbeat on data reported by other companies at the ACC conference. Medtronic's (MDT) data suggested that its CoreValve Evolut-R product may be as effective as Edwards' Sapien 3, Bernstein's Sung stated. The FDA appears to have allowed Boston Scientific's (BSX) left atrial appendage closure, Watchman, to be provided to more patients than expected, research firm Stifel believes. Meanwhile, St. Jude's (STJ) CardioMEMS device yielded "impressive" mortality data, the firm added. Stifel kept Buy ratings on both Medtronic and St. Jude. PRICE ACTION: In early afternoon trading, Edwards Lifesciences climbed 9% to $147.64, Boston Scientific advanced 4% to $17.27, St. Jude added 2% to $67.55, and Medtronic rose 1.3% to $77.50.
07:30 EDTMDTAmerican College of Cardiology to hold an expo
Subscribe for More Information
07:22 EDTMDTMedtronic Edwards Lifesciences data 'impressive,' says Bernstein
Subscribe for More Information
March 15, 2015
18:04 EDTKODavid Winters says Coca-Cola CEO declined bonus not enough, Reuters says
Subscribe for More Information
15:27 EDTMDTMedtronic unveils data from high risk study of the CoreValve U.S. pivotal trial
Subscribe for More Information
15:23 EDTMDTMedtronic unveils preclinical outcomes of its novel Drug-Filled Stent
Subscribe for More Information
15:20 EDTMDTMedtronic announces outcomes for its next-generation CoreValve Evolut R System
Medtronic announced initial clinical outcomes for its next-generation CoreValve Evolut R System. At 30-days, the new recapturable, self-expanding valve showed no incidents of all-cause mortality or stroke in a high and extreme risk patient population. Data from the Evolut R Study, which enrolled 60 patients from six centers in the United Kingdom, Australia and New Zealand, were unveiled today at the 64th Annual Scientific Session of the American College of Cardiology. The CoreValve Evolut R System is not approved for commercial use in the United States where it is currently undergoing clinical trials. "Initial clinical experience with the Evolut R system is remarkable and ushers in a new era of TAVR technology that provides increased confidence with recapturability, excellent procedural results, and impressive clinical outcomes," said Ian Meredith, M.D., of Monash Heart - Monash Health, Melbourne, Australia, who is one of the investigators of the study. "The 14 French equivalent delivery system allowed transfemoral access for most patients and the recapturable technology enabled implanters to optimize valve placement for improved annular sealing and reduced conduction disturbances without compromise on mortality or stroke."
March 12, 2015
09:32 EDTMDTMedtronic announces start of Resolute Onyx studies in U.S.
Medtronic announced the start of its Resolute Onyx Clinical Program in the United States, which will evaluate the Resolute Onyx drug-eluting stent in patients who have coronary artery disease. Included in the first phase of the study are patients with small vessels that would require a 2.0 mm stent, which until now, often were untreatable with a DES. Core sizes of the stent will be studied separately.
07:18 EDTKOCoca-Cola outlook has improved, says Wells Fargo
After meeting with Coca-Cola's CFO, Wells Fargo is more confident that the company's revenue growth can accelerate. The firm is encouraged by what it sees as the company's ability to drive share gains and net price realization through its increased media spend and best-in-class price/pack architecture. Wells keeps an Outperform rating on the shares. .
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use